Subsequently, we identified a FSCN1 inhibitor, NP-G2-044, currently in phase Ib/IIa clinical trials for treating tumor invasion or metastasis.19 Next, mouse chondrocytes were treated with IL-1β with or without NP-G2-044. This evidence concerns the gene IL1B and neoplasm.